Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Janssen discontinues phase III development of fulranumab for osteoarthritis pain

April 4, 2016

Anika Therapeutics receives CE Mark approval for Cingal

March 30, 2016

Samumed divulges Wnt signaling inhibitors

March 23, 2016

Kalytera partners with Ramot for osteogenesis imperfecta treatment research

March 18, 2016

Orphan drug designation granted in Japan for tocilizumab in systemic scleroderma

March 18, 2016

Study results support every-other-month dosing of gerilimzumab for rheumatoid arthritis

March 18, 2016

ProMetic Life Sciences to explore use of PBI-4050 for scleroderma

March 16, 2016

BMS reports data on BMS-986142

March 14, 2016

Phase III data show sarilumab superior to adalimumab in patients with active rheumatoid arthritis

March 11, 2016

Han Wha Pharma and Yang Ji Chemical disclose JAK inhibitors

March 11, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...